Use of targeted next-generation sequencing to detect drug-resistant tuberculosis: rapid communication, July 2023

A rapid communication released by the World Health Organization (WHO) Global Tuberculosis Programme announces upcoming updates to the guidance on the use of targeted next-generation sequencing for diagnosis of drug-resistant tuberculosis (DR-TB). This test represents a major advance in diagnostic technology and provides an option for rapid and accurate genetic analysis and detection of mutations associated with resistance in a fraction of the time required for culture-based methods for detecting resistance.

This Rapid Communication is released in advance of updated WHO consolidated guidelines expected later in 2023 to inform national TB programmes and other stakeholders of key changes in the available options for detection of TB drug resistance and to allow for rapid transition and planning at the country level. Further guidance will also be announced soon covering practical information on the steps to introduction of sequencing and the updated catalogue of mutations.